Royal Philips

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment businesses; Connected Care businesses; Personal Health businesses; and Other. The Diagnosis and Treatment businesses segment consists systems, smart devices, software and services, powered by AI-enabled informatics-that support precision diagnoses and minimally invasive procedures in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care businesses segment consists Hospital Patient Monitoring, Emergency Care, Sleep & Respiratory Care and Connected Care Informatics. The Personal Health businesses segment consists of Oral Healthcare, Personal Care,Mother and Child Care. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

November 12, 2024 Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy solution. Philips Spectral CT 7500 RT marks the next step in personalized cancer care by integrating the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer treatment and planning.

Philips Spectral CT 7500 RT, world's first spectral 4DCT respiratory-gated imaging receives FDA 510(k) clearance

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips, that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions.

Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

Industry leaders collaborate to offer Philips clinically proven tools and resources to Aspen Dental patients, providing better care for more people CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a partnership with Aspen Dental ®, the largest group of branded dental offices, to bring Philips Sonicare, the No.1 dental professional-recommended sonic toothbrush brand worldwide, to Aspen Dental's national network of over 1,100 locations.

Philips and Aspen Dental launch multi-year Sonicare-brand partnership

PHG's third-quarter results reflect improved earnings but highlight challenges with declining sales in China and growth in other regions, showcasing mixed performance.

Philips Q3 Earnings Beat: Will Weak Outlook Drag the Stock Down?

Philips' Q3 earnings showed flat sales but improved margins, driven by better productivity and pricing, despite weak performance in China. Risks include significant exposure to the Chinese market and competition, while opportunities lie in cost-cutting, AI implementation, and global growth. Due to China's economic weakness, Philips revised its sales growth guidance down to 0.5-1.5%, affecting stock performance and future expectations.

Philips Stock Crashes On China Slump

Philips (PHG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -18.64% in 4 Weeks, Here's Why Philips (PHG) Looks Ripe for a Turnaround

CAMBRIDGE, Mass. & WASHINGTON--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA) today announced it will accelerate the predictive health monitoring of the Rapid Analysis of Threat Exposure (RATE) algorithm to support the well-being and readiness of active-duty service personnel for the U.S. Department of Defense (DoD). Over the next four years, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), will invest $25 million to make the tec.

Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Monday.

S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings

Philips faces challenges in China, but its overall fundamentals remain strong, with significant growth potential in other markets and segments like cardiovascular and ultrasound. Despite a 17% share price drop, Philips is undervalued at €24.20/share, presenting a compelling investment opportunity with an expected 11% annual EPS growth. The company shows margin improvements and resilience in various segments, indicating effective price hikes and operational adjustments amidst market uncertainties.

Philips: Looking Undervalued After Q3 Earnings Drop

ResMed

Investors looking for stocks in the Medical - Products sector might want to consider either Royal Philips (PHG) or ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

PHG vs. RMD: Which Stock Should Value Investors Buy Now?

Koninklijke Philips N.V. (NYSE:PHG ) Q3 2024 Results Conference Call October 28, 2024 5:00 AM ET Company Participants Leandro Mazzoni - Head of Investor Relations Roy Jakobs - Chief Executive Officer Charlotte Hanneman - CFO Conference Call Participants Richard Felton - Goldman Sachs Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Lisa Clive - Bernstein Graham Doyle - UBS Hugo Solvet - Exane BNP Paribas Julien Dormois - Jefferies Robert Davies - Morgan Stanley Falko Friedrichs - Deutsche Bank Ed Ridley-Day - Redburn Leandro Mazzoni Hi, everyone.

Koninklijke Philips N.V. (PHG) Q3 2024 Earnings Call Transcript

Clear Channel Outdoor Holdings

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.

Philips Posts Weak Earnings, Joins Clear Channel Outdoor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

American depositary receipts (ADRs) of Koninklijke Philips (PHG) are tumbling more than 15% in premarket trading Monday after the Dutch conglomerate cut its 2024 sales outlook amid a "significant deterioration" in Chinese demand.

Philips Stock Tanks on Outlook Cut as Demand Deteriorates in China

On Monday, Koninklijke Philips NV PHG reported third-quarter adjusted EPS of 0.32 euros (or $0.35), missing the consensus of 0.35 euros.

Dutch Health Tech Firm Philips' Q3 Earnings Miss Expectations, Lowers Annual Forecasts On Weak Demand In China

It's a reminder of how sluggish demand in the world's second-largest economy could cause problems for the likes of Starbucks and Marriott.

China's Weak Economy Is Weighing on Stocks. Philips Is the Latest to Suffer.

Shares of Philips slumped on Monday as the Dutch healthcare devices company lowered its sales outlook for the year.

Philips shares slide as company blames China for lowered sales outlook

Philips said on Monday that demand in China slumped significantly in recent months, forcing the Dutch medical devices maker to lower its sales outlook for the year.

Philips cuts annual sales outlook as China demand deteriorates

October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growth Income from operations was EUR 337 million Adjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of sales Operating cashflow of EUR 192 million, with a free cashflow of EUR 22 million Comparable order intake decreased by 2%, due to decline in China Outlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range Roy Jakobs, CEO of Royal Philips: “In the quarter, demand from hospitals and consumers in China further deteriorated, while we continue to see solid growth in other regions. We have adjusted our full-year sales outlook to reflect the continued impact from China.

Philips delivers strong margin improvement; flat comparable sales due to further deteriorated demand in China; growth in rest of world

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Koninklijke Philips (PHG) Right Now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Royal Philips (PHG) is a Strong Momentum Stock

October 24, 2024 Both companies also join the newly established World Stroke Organization Advocacy Coalition Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability.

Philips and Medtronic advocacy partnership aims to help accelerate access to life-saving treatments

Generac Holdings

KinderCare Learning Cos Inc

Xeris Biopharma Holdings

The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises concerns for Dilantha De Silva about growth and customer churn, leading to a bearish stance despite recent stock gains. Fresenius Medical Care shows Wolf Report potential for growth despite recent earnings declines, with a BBB rating and attractive yield as rate cuts loom.

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

Investors with an interest in Medical - Products stocks have likely encountered both Royal Philips (PHG) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

PHG or RMD: Which Is the Better Value Stock Right Now?

Philips has transformed into a healthcare technology company but faces challenges from a massive respirator recall impacting reputation, sales, and stock valuation. Despite past struggles, Philips is integrating AI into products to enhance diagnostics and productivity, aiming for 5% revenue growth and 18% margins by 2026. The stock is discounted at 10x P/cash earnings, offering potential upside with a 2025 price target of $36 and a 2026 target of $39.

Philips: Moving Out Of Intensive Care

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News for Royal Philips Stock (PHG)